UK Markets open in 5 hrs 25 mins

Valbiotis SA (ALVAL.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
5.32-0.04 (-0.75%)
At close: 05:35PM CEST
Full screen
Previous close5.36
Open5.36
Bid0.00 x 0
Ask0.00 x 0
Day's range5.30 - 5.46
52-week range4.01 - 7.48
Volume6,832
Avg. volume11,531
Market cap51.549M
Beta (5Y monthly)0.67
PE ratio (TTM)N/A
EPS (TTM)-0.54
Earnings date30 Sept 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.00
  • Business Wire

    Valbiotis Announces the Release of the Universal Registration Document

    LA ROCHELLE, France, May 19, 2022--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / PME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces that its Universal Registration Document was filed to the French Financial Markets Regulator (AMF) May 19, 2022.

  • Business Wire

    Valbiotis - Combined Shareholders General Meeting Held on May 5, 2022

    LA ROCHELLE, France, May 06, 2022--Regulatory News: Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA / PME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces its Combined Shareholders Meeting was held on May 5, 2022 at Espace Encan, La Rochelle, under the chairmanship of Sébastien PELTIER, Chairman of the Board of Directors, and that all the resolutions submitted for voting have been adopted by its shareho

  • Business Wire

    Valbiotis Announces the First Visit of the First Patient in the TOTUM•63 Mode of Action Clinical Study Conducted by the INAF1, in Partnership With Nestlé Health Science

    LA ROCHELLE, France, April 28, 2022--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the first visit of the first patient in the TOTUM•63 mode of action clinical study conducted by the Laval University Institute of Nutrition and Functional Foods (INAF) in Quebec City, in partnership with Nestlé Health Science. The study has now b